Atul Bhardwaj

Atul Bhardwaj

Auto-generated profile, based on publicly available information

Atul Bhardwaj

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada T6G 2E1

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAtul Bhardwaj
Atul Bhardwaj
JKJatinder Kaur
Jatinder Kaur
MWMelinda Wuest
Melinda Wuest
Frank WuestFrank Wuest
Frank Wuest
Cyclooxygenase-2 isozyme is a promising anti-inflammatory drug target, and overexpression of this enzyme is also associated with several cancers and neurodegenerative diseases. The amino-acid sequence and structural similarity between inducible cyclooxygenase-2 and housekeeping cyclooxygenase-1 isoforms present a significant challenge to design selective cyclooxygenase-2 inhibitors. Herein, we describe the use of the cyclooxygenase-2 active site as a reaction vessel for the in situ generation of its own highly specific inhibitors. Multi-component competitive-binding studies confirmed that the cyclooxygenase-2 isozyme can judiciously select most appropriate chemical building blocks from a pool of chemicals to build its own highly potent inhibitor. Herein, with the use of kinetic target-guided synthesis, also termed as in situ click chemistry, we describe the discovery of two highly potent and selective cyclooxygenase-2 isozyme inhibitors. The in vivo anti-inflammatory activity of these two novel small molecules is significantly higher than that of widely used selective cyclooxygenase-2 inhibitors.


10 March 2023 in Science Immunology
Verified
Journal Article
Closed access
YZYini Zhu
Yini Zhu
YZYun Zhao
Yun Zhao
JWJiling Wen
Jiling Wen
SLSheng Liu
Sheng Liu
THTianhe Huang
Tianhe Huang
Xin LuXin Lu
Xin Lu
The noninflamed microenvironment in prostate cancer represents a barrier to immunotherapy. Genetic alterations underlying cancer cell–intrinsic oncogenic signaling are increasingly appreciated for their role in shaping the immune landscape. Recently, we identified Pygopus 2 ( PYGO2 ) as the driver oncogene for the amplicon at 1q21.3 in prostate cancer. Here, using transgenic mouse models of metastatic prostate adenocarcinoma, we found that Pygo2 deletion decelerated tumor progression, diminished metastases, and extended survival. Pygo2 loss augmented the activation and infiltration of cytotoxic T lymphocytes (CTLs) and sensitized tumor cells to T cell killing. Mechanistically, Pygo2 orchestrated a p53/Sp1/Kit/Ido1 signaling network to foster a microenvironment hostile to CTLs. Genetic or pharmacological inhibition of Pygo2 enhanced the antitumor efficacy of immunotherapies using immune checkpoint blockade (ICB), adoptive cell transfer, or agents inhibiting myeloid-derived suppressor cells. In human prostate cancer samples, Pygo2 expression was inversely correlated with the infiltration of CD8 + T cells. Analysis of the ICB clinical data showed association between high PYGO2 level and worse outcome. Together, our results highlight a potential path to improve immunotherapy using Pygo2-targeted therapy for advanced prostate cancer.

1 March 2012 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JKJatinder Kaur
Jatinder Kaur
ABAtul Bhardwaj
Atul Bhardwaj
ZHZhangjian Huang
Zhangjian Huang
EKEdward E. Knaus
Edward E. Knaus

1 January 2013 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ABAtul Bhardwaj
Atul Bhardwaj
JKJatinder Kaur
Jatinder Kaur
SSSai Kiran Sharma
Sai Kiran Sharma
ZHZhangjian Huang
Zhangjian Huang
FWFrank Wuest
Frank Wuest
EKEdward E. Knaus
Edward E. Knaus